Trial intelligence / Profile preview

Subcutaneous Velcade Combinations in Elderly MM

NCT01190787Phase 2

Key facts

Status: Completed
Start: Jul 2010
Primary completion: May 2012
Countries: 1
Modality: Small Molecules, Modified Peptides

Drugs: bortezomib
Conditions: multiple myeloma (MM)

Overview

Phase 2, randomised, open-label trial of bortezomib in multiple myeloma (MM) (3 arms). Primary endpoint: Very Good Partial Response, Complete response rate, Partial response rate at 5 years. Started Jul 2010; status: completed.

Design

3 arms

Study design: RandomizedOpen-label

VMP
Bortezomib (SC) + Melphalan (PO) + Prednisone (PO)
VCP
Bortezomib (SC) + Cyclophosphamide (PO) + Prednisone (PO)
VP
Bortezomib (SC) + Prednisone (PO)

Endpoints

Primary

Very Good Partial Response, Complete response rate, Partial response rate5 years

Secondary

Progression free survival5 years
Time to progression5 years
Time to Next Therapy5 years
Overall survival5 years
Time to response5 years
Duration of response5 years

Beyond the preview

Go deeper on NCT01190787.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01190787.